Background: SARS-CoV-2, a novel coronavirus that caused a pandemic respiratory disease, has recently emerged from China. Since it is a life-threatening virus, investigation of curative medications along with protective vaccines still maintains its importance. Drug repurposing is a reasonable and immediate approach to combat SARS-CoV-2 infection by identifying inhibitory molecules from marketed drugs. PL protease (PLpro) is one of the essential enzymes for the progression of SARS-CoV-2 replication and life cycle. Objective: We aimed to investigate the potential of 4 HCV protease inhibitors as probable repurposing drugs in Covid-19 treatment. Methods: In order to understand possible binding affinity of HCV protease inhibitors, Boceprevir, Grazoprevir, Simeprevir, and Telaprevir, against PLpro, we performed docking analysis in silico. Docking study was accomplished using AutoDock 4.2 Software. Potential druggable pockets on PLpro were predicted by DoGSiteScorer tool in order to explore any overlapping with binding regions and these pockets. Results: This analysis demonstrated Boceprevir, Grazoprevir, Simeprevir and Telaprevir interacted by PLpro with binding energies (kcal/mol) of -4.97, -4.24, -6.98, -1.08, respectively. Asn109, one of the interacted residues with both Boceprevir and Simeprevir, is a neighbouring residue to catalytic Cys111. Additionally, Telaprevir notably interacted with catalytic His272 in the active site. Conclusion: Present study explains the binding efficiency and repurposing potential of certain HCV protease inhibitors against to SARS-CoV-2 PLpro enzyme. Docking sites and potential druggability of ligands were also crosschecked by the estimation of druggable pockets. Thereby our results can promote promising preliminary data for research on drug development in the fight of Covid-19.
30 April 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Background/aim: Macrothrombocytopenia is an autosomal-dominant disorder characterized by increased platelet size and a decreased number of circulating platelets. The membrane skeleton and the link between actin filaments of the skeleton and microtubules, which consist of alpha and beta tubulin [including the tubulin beta-1 chain (TUBB1)] heterodimers, are important for normal platelet morphology, and defects in these systems are associated with macrothrombocytopenia. Materials and methods: In this study, we sequenced the exons of the TUBB1 gene using DNA isolated from the peripheral blood samples of healthy controls (n = 47) and patients with macrothrombocytopenia (n = 37) from Turkey. The TUBB1 expression levels in fractioned blood samples from patients and healthy controls were analyzed by RT-qPCR and Western blot. Microtubule organization of the platelets in the peripheral blood smears of patients, and in mutant TUBB1-transfected HeLa cells, were analyzed by immunofluorescence staining. Results: A new TUBB1 c.803G > T (p.T178T) variant was detected in all of the control and patient samples. Importantly, we found 3 new heterozygous TUBB1 variants predicting amino acid substitutions: G146R (in 1 patient), E123Q (in 1 patient), and T274M (in 4 patients); the latter variant was associated with milder thrombocytopenia in cancer patients treated with paclitaxel. Ectopic expression of TUBB1 T274M/R307H variant in HeLa cells resulted in irregular microtubule organization. Conclusion: Further clinical and functional studies of the newly identified TUBB1 variants may offer important insights into their pathogenicity in macrothrombocytopenia.
1 January 2025 in Journal of Clinical Practice and Research
Objective: Chemotherapy-induced nausea and vomiting (CINV) following antineoplastic drug administration in cancer patients significantly affects their quality of life and treatment adherence. The 5-hydroxytryptamine type 3A receptor (5-HT3A) (serotonin) is a key target involved in emetic signaling. Understanding the molecular interactions between chemotherapeutic agents and this receptor may aid in the development of more effective antiemetic therapies. This study aims to investigate the binding potential of commonly used chemotherapeutic drugs to the serotonin receptor to better understand their role in triggering emetic responses. Materials and Methods: A computer-aided protein-ligand docking analysis was performed using AutoDock4 and PyMol software to evaluate drug-receptor binding affinities. Frequently used chemotherapeutic agents (azacitidine, carboplatin, cyclophosphamide, dacarbazine, doxorubicin, lomustine, melphalan, and streptozocin) and standard antiemetics were analyzed in experimental groups, with serotonin used as a control in the computational study. Results: The chemotherapeutic agents demonstrated significantly higher binding potential compared to antiemetics and serotonin. Notably, these antineoplastic drugs were shown, for the first time, to interact with common amino acids, compared to antiemetics, and serotonin, suggesting that chemotherapy drugs might compete with them for binding to the 5-HT3A receptor and thereby exacerbate nausea and vomiting during chemotherapy administration. Conclusion: Chemotherapy-induced nausea and vomiting are known to result indirectly from serotonin released by damaged intestinal cells in response to the toxic side effects of chemotherapy drugs. However, this study remarkably proposes an alternative mechanism for CINV and presents the first evidence of a direct interaction between certain antineoplastic drugs and the serotonin receptor.